Management ChangeJun 1, 2026, 04:32 PM
West Pharma Appoints Michel Lagarde as New CEO, Effective Aug 31
AI Summary
West Pharmaceutical Services, Inc. announced the appointment of Michel Lagarde as its new President and Chief Executive Officer, effective August 31, 2026. Mr. Lagarde, previously Executive Vice President and COO at Thermo Fisher Scientific, will also join the Board of Directors. He succeeds Eric M. Green, who will retire from his roles as President, CEO, and Board Chair on the same date. Robert F. Friel, the current Lead Independent Director, will become the new Board Chair. Mr. Lagarde's compensation package includes an annual base salary of $1,175,000, a target annual incentive award of 125% of his salary, and significant equity awards.
Key Highlights
- Michel Lagarde appointed President and CEO of West Pharmaceutical Services, effective August 31, 2026.
- Eric M. Green will retire as President, CEO, and Board Chair on August 31, 2026.
- Lead Independent Director Robert F. Friel will become Board Chair, effective August 31, 2026.
- Mr. Lagarde's annual base salary will be $1,175,000.
- He will have a target annual incentive award of 125% of his salary, or $1,468,750.
- Mr. Lagarde will receive 2026 long-term incentive awards with a total grant value of $8,611,111.
- He will also receive one-time inducement equity awards up to $10,000,000, including a $6,875,000 sign-on grant.
- Matching inducement grants are based on personal stock purchases up to $2,500,000.
Price Impact
More from WST